share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Apr 18 05:50
Summary by Futu AI
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on April 15, 2024, involving the sale of company shares. Kulkarni sold a total of 19,582 shares of common stock at prices ranging from $59.8819 to $60.4003, resulting in a total market value of approximately $1,173,231.52. Prior to the sales, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on April 15, 2024, involving the sale of company shares. Kulkarni sold a total of 19,582 shares of common stock at prices ranging from $59.8819 to $60.4003, resulting in a total market value of approximately $1,173,231.52. Prior to the sales, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.